| Literature DB >> 32416922 |
Nihar Kinarivala1, Lisa C Standke2, Tezcan Guney1, Cheng Ji1, Naoyoshi Noguchi3, Yasutomi Asano3, Derek S Tan4.
Abstract
Salicyl-AMS (1) is a potent inhibitor of salicylate adenylation enzymes used in bacterial siderophore biosynthesis and a promising lead compound for the treatment of tuberculosis. An optimized, multigram synthesis is presented, which provides salicyl-AMS as its sodium salt (1·Na) in three synthetic steps followed by a two-step salt formation process. The synthesis proceeds in 11.6% overall yield from commercially available adenosine 2',3'-acetonide and provides highly purified material.Entities:
Keywords: Antibiotic; Drug development; Tuberculosis
Mesh:
Substances:
Year: 2020 PMID: 32416922 PMCID: PMC7367610 DOI: 10.1016/bs.mie.2020.04.051
Source DB: PubMed Journal: Methods Enzymol ISSN: 0076-6879 Impact factor: 1.600